AVDL News and Press, Avadel Pharmaceuticals plc From 02/08/23

DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Con...

- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose - DUBLIN, Ireland, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused ...

Summary Avadel's LUMRYZ in treatment of cataplexy in adults with narcolepsy received tentative FDA approval, temporarily blocked by a patent owned by Jazz Pharmaceuticals. The situation creates a David vs. Goliath match-up of great importance for both companies. Jazz is taking the f...

Summary Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy. We rate AVDL a buy now with the overhang removed, with far more clarity on the route to full FDA approval...

- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...

Ireland-based biopharma Avadel Pharmaceuticals ( NASDAQ: AVDL ) added ~26% on Friday to reach the highest level since March, as Needham noted that recent comments made by the Federal Trade Commission (FTC) could lead to imminent FDA approval for its lead asset Lumryz. FD...

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare C...

Avadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Conference Call November 09, 2022, 08:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Offic...

Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q3 GAAP EPS of -$0.33 misses by $0.07 . Cash, cash equivalents and marketable securities were $106.5 million as of September 30, 2022. Also, as of September 30, 2022, the Company had $26.4 million of convertibl...

LUMRYZ™ granted tentative approval on July 18, confirming its safety profile and clinical efficacy Final approval decision of LUMRYZ expected by June 2023; advancing strategy to potentially accelerate final approval Commercial launch planned for no later t...